Apotex acquisition likely to reduce Aurobindo's dependence on US market

The Apotex acquisition will further strengthen Aurobindo's position among the top 10 pharma companies by sales in Europe

The recently announced acquisition of Apotex International's commercial operations in five European countries by Aurobindo Pharma Limited, once completed, will narrow the gap between the company's US and European revenues as its plan to end its dependence on a single market fast becomes a reality. 

Earlier this month, Aurobindo entered a definitive agreement with the Canadian pharmaceutical company to acquire the latter's commercial infrastructure, including personnel, products, marketing authorisations and dossier license rights, in the Netherlands, Poland, Spain, Czech Republic and Belgium.

A euro 74-million (Rs 5.92 billion) all-cash deal brings to Aurobindo's fold operations with reported sales of euro 133 million